Clemens-martin M. Wendtner
Elite in Chronic B-Cell Leukemia (CBCL)

Clemens-martin M. Wendtner

Munich, BY, DE 
Elite in Chronic B-Cell Leukemia (CBCL)
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Clemens-martin Wendtner practices in Munich, Germany. Wendtner is rated as an Elite expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Their top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, and Small Lymphocytic Lymphoma (SLL).

Their clinical research consists of co-authoring 114 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 71 articles in the study of Chronic B-Cell Leukemia (CBCL).

Locations

Munich, BY, Germany
Other Locations
Oberschleissheim, BY 85764, Germany
Dresden, SN, Germany
St. Marien Hospital, Homburg, SL, Germany
Koeln, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Enrollment Status: Unknown
Publish Date: April 27, 2023
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Bortezomib, Autologous Stem Cell Transplant, Aallogeneic Stem Cell Transplant
Study Phase: Phase 3
A Prospective, Multicenter, Phase-II Trial Evaluating Efficacy and Safety of Bendamustine + GA101 (BG) in Patients With Relapsed CLL Followed by Maintenance Therapy With GA101 for Responding Patients
A Prospective, Multicenter, Phase-II Trial Evaluating Efficacy and Safety of Bendamustine + GA101 (BG) in Patients With Relapsed CLL Followed by Maintenance Therapy With GA101 for Responding Patients
Enrollment Status: Unknown
Publish Date: August 13, 2018
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 1 Less Clinical Trial

114 Total Publications

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Journal: Blood
Published: February 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wendtner's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile